Trial Profile
OCTUMI-4: Evaluation of Mirtazapine and Folic Acid for Schizophrenia: A Large Simple 2x2 Factorial Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Folic acid (Primary) ; Mirtazapine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms OCTUMI-4; RECOVERY
- 14 Nov 2013 Accrual to date is 17% according to United Kingdom Clinical Research Network.
- 17 Jul 2013 Accrual to date is 21% according to United Kingdom Clinical Research Network.
- 16 Jun 2013 Accrual to date is 19% according to United Kingdom Clinical Research Network.